Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports


Eosinophilic fasciitis, Shulman's disease, tolicizumab


Fasciitis with eosinophilia (FE) is a rare connective tissue disease. Due to its rarity, large-scale studies are lacking, which makes its treatment challenging. Systemic corticosteroids (SCSs) are the cornerstone of treatment; however, additional immunosuppressive drugs (ISDs) are frequently necessary (usually methotrexate). We report 2 patients, for whom an SCS and methotrexate were not a viable long-term option. In the first case, we were unable to taper the SCS dose without symptom relapse, the patient showed only a partial response to methotrexate and presented side effects. The second case never fully responded to the SCS and methotrexate and demonstrated serious SCS adverse effects. Both patients were started on tocilizumab with extremely favourable results, making this drug a potential therapeutic weapon for these patients.



  • Pinal-Fernandez I, Selva-O’Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014;13(4–5):379–382.

  • Lebeaux D, Sène D. Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 2012;26(4):449–458.

  • Mazori DR, Femia AN, Vleugels RA. Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep 2017;19(12):74.

  • Thomson GTD, Johnston JL, Thomson BRJ. Eosinophilic fasciitis treated with tocilizumab: demonstration of efficacy after withdrawal and re-challenge in a patient. J Rheum Dis Treat 2015;1(3):021.

  • Espinoza F, Jorgensen C, Pers Y. Efficacy of tocilizumab in the treatment of eosinophilic fasciitis: report of one case. Joint Bone Spine 2015;82(6):460–461.
  • Views: 1193
    HTML downloads: 169
    PDF downloads: 509

    Published: 2020-03-02
    Issue: 2020: Vol 7 No 4 (view)

    How to cite:
    Pinheiro G, Costa AR, Campar A, Mendonça T. Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports. EJCRIM 2020;7 doi:10.12890/2020_001485.